SCICLONE PHARMACEUTICALS INC Balance Sheet

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Balance Sheets

In millions of USD, except per-share amounts

	Q2 FY2017 As of Jun 30, 2017	Q1 FY2017 As of Mar 31, 2017	Q4 FY2016 As of Dec 31, 2016	Q3 FY2016 As of Sep 30, 2016	Q2 FY2016 As of Jun 30, 2016	Q1 FY2016 As of Mar 31, 2016	Q4 FY2015 As of Dec 31, 2015	Q3 FY2015 As of Sep 30, 2015	Q2 FY2015 As of Jun 30, 2015	Q1 FY2015 As of Mar 31, 2015	Q4 FY2014 As of Dec 31, 2014	Q3 FY2014 As of Sep 30, 2014	Q2 FY2014 As of Jun 30, 2014	Q1 FY2014 As of Mar 31, 2014	Q4 FY2013 As of Dec 31, 2013	Q3 FY2013 As of Sep 30, 2013	Q2 FY2013 As of Jun 30, 2013	Q1 FY2013 As of Mar 31, 2013	Q4 FY2012 As of Dec 31, 2012	Q3 FY2012 As of Sep 30, 2012
ASSETS
Current assets:
Cash and cash equivalents
Restricted cash in escrow for SEC settlement (Note 15)
Accounts receivable, net of allowances of $0 and $0 as of June 30, 2017 and December 31, 2016, respectively
Inventories
Restricted cash and investments
Short-term investments
Prepaid expenses and other current assets
Deferred tax assets
Total current assets
Property and equipment, net
Deferred tax assets
Investment in third party (Note 4)
Goodwill
Other assets
Total assets

LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable
Accrued and other current liabilities
Deferred revenue
Deferred tax liabilities
Short-term borrowing on loan facility
Contingent consideration
Short-term borrowings on loan facility
Contingent consideration (earn-out) at estimated fair value
Total current liabilities

Deferred tax liabilities
Total current liabilities
Other long-term liabilities
Stockholders' equity:
Common stock; $0.001 par value; 100,000,000 shares authorized; 52,191,854 and 51,236,952 shares issued and outstanding as of June 30, 2017 and December 31, 2016, respectively
Additional paid-in capital
Accumulated other comprehensive loss
Accumulated deficit
Total stockholders' equity
Total liabilities and stockholders' equity

Comments